Last reviewed · How we verify
Tafluprost ophthalmic solution 0.0015%
Tafluprost is a prostaglandin F2α analogue that reduces intraocular pressure by increasing uveoscleral outflow.
Tafluprost is a prostaglandin F2α analogue that reduces intraocular pressure by increasing uveoscleral outflow. Used for Glaucoma, ocular hypertension.
At a glance
| Generic name | Tafluprost ophthalmic solution 0.0015% |
|---|---|
| Sponsor | Santen Pharmaceutical Co., Ltd. |
| Drug class | Prostaglandin analogue |
| Target | Prostaglandin F2α receptor |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 3 |
Mechanism of action
Tafluprost works by mimicking the action of prostaglandin F2α, a naturally occurring substance in the body that helps to regulate intraocular pressure. By increasing uveoscleral outflow, tafluprost reduces the amount of fluid in the eye, thereby lowering intraocular pressure. This mechanism of action is similar to other prostaglandin analogues used to treat glaucoma and ocular hypertension.
Approved indications
- Glaucoma, ocular hypertension
Common side effects
- Eyelid skin darkening
- Iris pigmentation changes
- Periorbital fat atrophy
- Dry eye
- Eye pain
Key clinical trials
- A Study of DE-111A on the Treatment of Open Angle Glaucoma or Ocular Hypertension (PHASE3)
- Prospective, Single Center Switching Study of 0.0015% Tafluprost Ophthalmic Solution in Primary Open-angle Glaucoma and Ocular Hypertension Patients With Corneal Disorders (Switching From 0.005% Latanoprost Ophthalmic Solution) (NA)
- Tafluprost Preservative Free Switch Study (PHASE4)
- Comparison Between Latanoprost , Travoprost and Tafluprost in Reducing IOP Fluctuation in POAG Patients
- Preservative-Free Tafluprost (MK-2452) for the Treatment of Open-Angle Glaucoma or Ocular Hypertension (MK-2452-002) (PHASE3)
- The Secondary Beneficial Effects of Prostaglandin Analog Treatment in Thyroid Eye Disease Patients. (PHASE4)
- A Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Patients With POAG or OHT (PHASE1, PHASE2)
- A Study to Evaluate Pharmacokinetics of Tafluprost Ophthalmic Solution (0.0015%) in Pediatric Patients With Glaucoma or Ocular Hypertension (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: